What is HC Wainwright’s Forecast for FULC Q1 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research report issued on Tuesday, February 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.29). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.79 EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31).

Several other research analysts have also recently issued reports on FULC. Royal Bank Of Canada raised their target price on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a report on Monday, December 8th. Cantor Fitzgerald increased their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research note on Tuesday. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Fulcrum Therapeutics Trading Down 2.8%

FULC opened at $8.73 on Thursday. The firm has a 50 day moving average of $10.66 and a two-hundred day moving average of $9.47. The firm has a market capitalization of $581.42 million, a PE ratio of -7.40 and a beta of 3.19. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74.

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently bought and sold shares of the company. Braidwell LP boosted its stake in shares of Fulcrum Therapeutics by 1,294.7% in the fourth quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after acquiring an additional 2,841,734 shares during the last quarter. Siren L.L.C. acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $22,054,000. First Turn Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $21,406,000. GSK plc acquired a new position in Fulcrum Therapeutics during the fourth quarter worth $20,196,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares during the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near-term loss forecasts across Q1–Q4 2026 (from about ($0.29) to ($0.28) per quarter) and raised FY2026 and FY2027 EPS (less negative), while reiterating a “Buy” rating and a $25 price target — a vote of confidence that supports upside if clinical/catalyst risk eases. MarketBeat FULC
• Positive Sentiment: Stifel published commentary saying Fulcrum’s recent share decline looks “overdone,” which may attract value-oriented buyers and provide short-term buying support. Stifel: Move Lower Overdone
• Positive Sentiment: HC Wainwright also published long-term upside forecasts (FY2030 EPS est. $2.71) that, together with the $25 target, highlight a multi-year recovery scenario if clinical programs and commercialization prospects succeed. MarketBeat FULC
• Neutral Sentiment: Fulcrum’s Q4 2025 results and earnings call largely met expectations (reported EPS approx. ($0.31) in line with consensus), so there were no large surprise beats to drive the stock higher — the quarter appears already priced in. Q4 2025 Earnings Call Summary
• Negative Sentiment: News that the stock “tumbled despite trial results” suggests the market was disappointed by the clinical readouts’ details, commercial implications, or guidance — that selling pressure appears to be the primary driver of today’s weakness. Investing.com: Stock Tumbles
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS modestly (FY2028 to $0.87 from $0.94; FY2029 to $1.79 from $1.91), signaling slightly lower long-term revenue/profit expectations and tempering the bullish long-term case. MarketBeat FULC

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.